Irvine, CA - A court injunction preventing the sale of Medtronic's CoreValve in Germany went into effect yesterday, the manufacturer of the CoreValve's chief competitor, Edwards Lifesciences, ...

Siegburg, Germany - Percutaneous implantation of the self-expanding CoreValve aortic valve bioprosthesis in the first-ever series of patients shows that the procedure is feasible in those deemed too ...

Medtronic's CoreValve system today gained a second indication from the FDA for use in patients with severe aortic stenosis who are at high risk for surgery. The transcatheter aortic valve replacement ...

Leading medical device major Medtronic Inc.'s (MDT) self-expanding CoreValve transcatheter aortic valve system recently exhibited cost efficiency in transcatheter aortic valve replacement (:TAVR) ...

Add Yahoo as a preferred source to see more of our stories on Google. NEW YORK (AP) -- Medtronic said Monday that a federal appeals court has ruled it can continue selling its CoreValve heart valve ...

The FDA today approved Medtronic's CoreValve transcatheter aortic valve replacement (TAVR) system for patients with severe aortic stenosis who are unable to undergo conventional open-heart surgery.

Ireland-based medical device major Medtronic plc MDT has been in the headlines over the past few weeks owing to multiple regulatory approvals and the release of positive study results, particularly ...

Meta-Analysis of Seven International Clinical Registries Presented at EuroPCR 2011 Late-Breaking Presentation PARIS – A late-breaking presentation about transcatheter aortic valve implantation (TAVI) ...

IRVINE, Calif.--(BUSINESS WIRE)--CoreValve (www.corevalve.com) announced today that it has signed a definitive agreement to be acquired by Medtronic, Inc. (NYSE: MDT). CoreValve’s transcatheter, ...

Medtronic, Inc. 's ( MDT) CoreValve transcatheter aortic valve replacement (TAVR) system continues to provide efficient treatment at two years for extreme-risk patients, the company announced at the ...

Leading medical devices player, Medtronic (NYSE:MDT - News) has taken one step forward in its CoreValve US pivotal trial with completion of enrollment in the extreme risk category of patients. The ...

Approximately 1 in 3 patients with severe aortic stenosis who undergo transcatheter aortic valve implantation (TAVI) with the CoreValve device will require a permanent pacemaker within 30 days of the ...